Is 4ZU undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6
Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 4ZU when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate 4ZU's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 4ZU's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 4ZU?
Key metric: As 4ZU is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
The above table shows the Price to Sales ratio for 4ZU. This is calculated by dividing 4ZU's market cap by their current
revenue.
What is 4ZU's PS Ratio?
PS Ratio
8x
Sales
US$892.00k
Market Cap
US$7.10m
4ZU key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Price-To-Sales vs Industry: 4ZU is good value based on its Price-To-Sales Ratio (7.4x) compared to the European Biotechs industry average (8x).
Price to Sales Ratio vs Fair Ratio
What is 4ZU's PS Ratio
compared to its
Fair PS Ratio?
This is the expected PS Ratio taking into
account the company's forecast earnings growth, profit margins
and other risk factors.
4ZU PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio
8x
Fair PS Ratio
8x
Price-To-Sales vs Fair Ratio: 4ZU is good value based on its Price-To-Sales Ratio (7.4x) compared to the estimated Fair Price-To-Sales Ratio (7.8x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.